This might be related to the fact that, over the last several decades, pharmacological research regarding NRF2 modulating drugs has focused on NRF2-activating rather than -inhibiting drugs, with the primary goal to enhance cellular tolerance towards ROS, which might be beneficial in a plethora of degenerative disorders but is probably less promising as a novel concept in tumour treatment [255]. The gene discussed is NFE2L2; the disease is neoplasm.